Tacrolimus (topical)

A calcineurin inhibitor ointment, FDA-approved as second-line short-term treatment for moderate to severe eczema (atopic dermatitis), ages 2 and older.

psilodex.org/m/tacrolimus-topical · data v2026.10.04

Clinical contraindication: None listed; No clinical contraindication identified.
Psilocybin evidence: No psilocybin data
Half-life: Not stated in label or references; The ~43–48 h value comes from IV/oral studies, not ointment use; no topical value.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Tacrolimus (topical)”, v2026.10.04. psilodex.org/m/tacrolimus-topical

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

Availability

FDA-approved for

Moderate to severe atopic dermatitis, second-line, short-term and non-continuous chronic treatment (0.03% ages 2–15; 0.03% and 0.1% adults)

Sources [1]

01 Interaction with psilocybin

No known interaction with psilocybin; its label describes minimal absorption into the blood from the ointment.

Detail No known interaction. The label states tacrolimus is minimally absorbed after ointment use, with most patients' peak blood levels under 2 ng/mL, so oral tacrolimus's blood pressure, QT and seizure warnings describe a much higher exposure. Sources [1]

No reported interaction is not a finding of safety: most combinations with psilocybin have never been studied.

Human data with psilocybin: None known: no published human data with psilocybin

Evidence types on this record

No psilocybin dataNo psilocybin data; record based on general references (product label, reference works, reviews)

02 Pharmacology relevant to psilocybin

None listed

No pharmacology properties of concern are listed for this record.

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Tacrolimus ointment 0.03% / 0.1% (generic of Protopic) · FDA label (DailyMed) — revised 2025-10-09 | Boxed warning: long-term safety of topical calcineurin inhibitors not established; rare malignancy reports | interaction: "tacrolimus is minimally absorbed after the topical application of tacrolimus ointment"
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-03Last reviewed against its sources.

Report an error in this record →